Impact of the CSM advice on thioridazine on general practitioner prescribing behaviour in Leeds: Time series analysis

British Journal of General Practice

Volumn 54, Issue 502, 2004, Pages 370-373

  Wright, Nat M J ^a   Roberts, Alison J ^b   Allgar, Victoria L ^a   Tompkins, Charlotte N E ^c   Greenwood, Darren C ^d   Laurence, Gillian ^e  

^a Centre for Research in Primary Care   (United Kingdom)

^b Bellbrooke Surgery   (United Kingdom)

^c NFA Health Centre for Homeless People   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e East Leeds PCT ^*  (United Kingdom)

Author keywords

General practitioner prescribing; Long QT syndrome; Prescribing advice; Primary health care; Psychotropic drugs; Telefacsimile

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; THIORIDAZINE;

ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG SAFETY; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HEALTH CARE ORGANIZATION; HUMAN; PHYSICIAN ATTITUDE; PRESCRIPTION; QUALITY CONTROL; STATISTICAL ANALYSIS; TIME SERIES ANALYSIS; UNITED KINGDOM;

ANTIPSYCHOTIC AGENTS; DRUG APPROVAL; ENGLAND; FAMILY PRACTICE; HUMANS; LONG QT SYNDROME; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; SAFETY; SCHIZOPHRENIA; THIORIDAZINE;

EID: 2342639553     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Committee on the Safety of Medicines. Thioridazine: restricted indications and new warnings on cardiotoxicity. London: Committee on the Safety of Medicines, 2000.
2. Prescription Pricing Authority. PACT Standard Report. Newcastle: Prescription Pricing Authority, 1999.
3. Ramsay S. UK 'pill scare' led to abortion increase. Lancet 1996; 347(9008): 1109.
4. Cochrane D, Orcutt GH. Application of least-squares regression to relationships containing autocorrelated error terms. J Am Stat Assoc 1949; 44: 32-61.
5. Judge GG, Griffiths WE, Hill RC et al. The theory and practice of econometrics (2nd edn). New York: John Wiley and Sons, 1985.
6. Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355(9209): 1048-1052.
7. Kitayama H, Kiuchi K, Nejima J et al. Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease. Eur J Clin Pharmacol 1999; 55(4): 259-262.
8. Zarate CA Jr, Patel J. Sudden cardiac death and antipsychotic drugs: do we know enough? Arch Gen Psychiatry 2001; 58(12): 1168-1171.
9. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000; 56(1): 1-18.
10. Wright N. Removal of thioridazine from primary care formulary will result in prescribing vacuum. BMJ 2001; 323(7314): 695.
11. Ray WA, Meredith S, Thapa PB et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58(12): 1161-1167.
12. Prescribing Pricing Authority. Update on growth in prescription volume and cost. Year to September 2002. Newcastle: Prescription Pricing Authority, 2002.